Syndax Pharmaceuticals Inc

SNDX is in a Stage 2 advance with a bullish medium-term tradable side, evidenced by sustained higher highs and lows and price holding above the 50DMA. A recent pullback into the short EMAs and 50DMA on light volume shows constructive consolidation rather than exhaustion, suggesting a favorable entry zone on a further shallow retracement into the EMA support area.

• ↑Q1 revenue of $64.9M (+224% YoY) led by Revuforge net sales of $48.9M (+144% YoY)
• ↑Approximately 330 new patients started Revuforge therapy in Q1, underlining adoption momentum
• ↓Negative profitability metrics and poor earnings yield suggest valuation risks